Allakos’s lirentelimab did not beat a placebo in separate Phase 2 tests in atopic dermatitis and spontaneous chronic urticaria. A restructuring now turns the biotech’s focus to an early-stage drug candidate also designed to treat inflammation.
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Engine Biosciences closed a $43 million Series A financing that the startup will apply to its artificial intelligence-based technology for drug discovery. The company analyzes genetic interactions, "deciphering biology" to find new cancer drugs.
The company said the agency told it that it may consider data from an amended version of the trial of LN-145 for approval. An analyst wrote that approval could happen in the first half of 2021, based on Iovance's guidance for regulatory submission.
This San Carlos biotech company is hoping to prove the clinical effectiveness of a T-cell therapy to treat solid tumors such as metastatic melanoma.
Stem cell therapy is one way the government’s preparing for a nation impacted by nuclear disaster. Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning. If approved, the feds could buy the drug for the Strategic National Stockpile, which is a part of Project Bioshield – a portion of the Bush-era […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.